同侧与对侧早期实质强化动力学的差异可预测乳腺癌新辅助治疗反应
研究纳入24例经组织学确诊的浸润性乳腺癌患者,在新辅助治疗前后行超快动态对比增强MRI(3-7秒/帧),计算肿瘤及双侧正常实质的4项动力学参数。治疗前双侧正常实质BPE30、BAT和AUC30相近者更易达到病理完全缓解(p<0.02);治疗后残留癌负荷II级者同侧正常实质的tSE30、肿瘤AUC30及MaxSlope高于I级或pCR者(p<0.05)。
要点
- 治疗前双侧正常实质BPE30、BAT、AUC30相近者更可能达到pCR(p<0.02)。
- 治疗后RCB II者同侧正常实质MaxSlope及肿瘤tSE30、AUC30高于RCB I或pCR者(p<0.05)。
- 超快DCE-MRI(3-7秒/帧)可同时评估肿瘤与双侧正常实质动力学。
核心结论
- 正常实质的双侧不对称性可在新辅助治疗前预测治疗结局,治疗后肿瘤动力学可评估残留肿瘤的侵袭性。
研究设计与样本
- 研究纳入24例经组织学确诊的浸润性乳腺癌患者,新辅助治疗前后行超快动态对比增强MRI(3-7秒/帧),在分割的肿瘤及同侧、对侧正常实质中计算4项动力学参数。
诊断标准与关键数值
- 治疗前同侧与对侧正常实质的BPE30、BAT、AUC30相近者更可能达到pCR(p<0.02)。
- 治疗后RCB II者同侧正常实质MaxSlope及肿瘤tSE30、AUC30高于RCB I或pCR者(p<0.05)。
- 动力学参数包括tSE30、BPE30、MaxSlope、BAT及AUC30。
临床应用与阅片要点
- 作者结论提示正常实质的双侧不对称性可在新辅助治疗前预测治疗结局。
- 作者结论提示治疗后肿瘤动力学可用于评估残留肿瘤的侵袭性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To determine whether kinetics measured with ultrafast dynamic contrast-enhanced magnetic resonance imaging in tumor and normal parenchyma pre- and post-neoadjuvant therapy (NAT) can predict the response of breast cancer to NAT.
MATERIALS AND METHODS: Twenty-four patients with histologically confirmed invasive breast cancer were enrolled. They were scanned with ultrafast dynamic contrast-enhanced magnetic resonance imaging (3-7 seconds/frame) pre- and post-NAT. Four kinetic parameters were calculated in the segmented tumors, and ipsi- and contra-lateral normal parenchyma: (1) tumor (tSE30) or background parenchymal relative enhancement at 30 seconds (BPE30), (2) maximum relative enhancement slope (MaxSlope), (3) bolus arrival time (BAT), and (4) area under relative signal enhancement curve for the initial 30 seconds (AUC30). The tumor kinetics and the differences between ipsi- and contra-lateral parenchymal kinetics were compared for patients achieving pathologic complete response (pCR) vs those who had residual disease after NAT. The chi-squared test and two-sided t-test were used for baseline demographics. The Wilcoxon rank sum test and one-way analysis of variance were used for differential responses to therapy.
RESULTS: Patients with similar pre-NAT mean BPE30, median BAT and mean AUC30 in the ipsi- and contralateral normal parenchyma were more likely to achieve pCR following NAT (p < 0.02). Patients classified as having residual cancer burden (RCB) II after NAT showed higher post-NAT tSE30 and tumor AUC30 and higher post-NAT MaxSlope in ipsilateral normal parenchyma compared to those classified as RCB I or pCR (p < 0.05).
CONCLUSION: Bilateral asymmetry in normal parenchyma could predict treatment outcome prior to NAT. Post-NAT tumor kinetics could evaluate the aggressiveness of residual tumor.
引用
- Ren, Pineda, Howard, et al. Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy. Acad Radiol. 2022. PMID: 35351365. doi:10.1016/j.acra.2022.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。